Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
about
Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas.Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?Tumor regression grade in gastric cancer: Predictors and impact on outcome.Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.[Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas.
P2860
Q26774533-DBF6584F-8F8A-4F25-9D3A-5CD1F154596FQ35633809-2F25B586-11C2-48B4-9B3F-F963BD30B059Q37681788-7BDDC814-451F-431D-A47E-99FE97009843Q38663129-C527D8EB-310D-4FB9-BB00-DDB78428FC8CQ39199654-4958EFC5-79E3-4B0B-91E6-74A03A0DF6B4Q40744902-8539FF09-379C-4013-AF4D-D373E47FA3FDQ40899349-611A626F-3D07-415A-A20A-11E918A2A22FQ41859828-128D2DB4-1A27-4DB4-B828-28B9C23B467BQ44802763-79ABB3A1-B503-4943-80F3-574E59BD5F63Q48166034-D44C160A-879E-4F81-8BF5-07F71618DA49Q53096881-4A2E61A6-0A59-4E50-967A-84E1C9B2F914Q53496643-ABE7E4AF-7FF8-4258-A279-E22F7092A7C6Q55241910-29A270F3-6AAF-4AA5-A369-C9AA4B3CBE6E
P2860
Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Factors predicting prognosis a ...... less than 10 % residual tumor.
@en
Factors predicting prognosis a ...... less than 10 % residual tumor.
@nl
type
label
Factors predicting prognosis a ...... less than 10 % residual tumor.
@en
Factors predicting prognosis a ...... less than 10 % residual tumor.
@nl
prefLabel
Factors predicting prognosis a ...... less than 10 % residual tumor.
@en
Factors predicting prognosis a ...... less than 10 % residual tumor.
@nl
P2093
P2860
P50
P1476
Factors predicting prognosis a ...... less than 10 % residual tumor.
@en
P2093
Annika Stange
Dirk Jäger
Florian Lordick
Karen Becker
Leila Sisic
Susanne Blank
Wilfried Roth
P2860
P2888
P304
P356
10.1007/S00423-012-1039-0
P407
P577
2012-12-27T00:00:00Z